Access the full text.
Sign up today, get DeepDyve free for 14 days.
(MurriRAmmassariATrottaMP Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 2004;19:1104–1015566439)
MurriRAmmassariATrottaMP Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 2004;19:1104–1015566439MurriRAmmassariATrottaMP Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 2004;19:1104–1015566439, MurriRAmmassariATrottaMP Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med 2004;19:1104–1015566439
A. Lippman (2005)
Adherence to medication.The New England journal of medicine, 353 18
F. Ross (1991)
Patient compliance--whose responsibility?Social science & medicine, 32 1
S. Perreault, A. Dragomir, L. Blais, A. Bérard, L. Lalonde, M. White (2008)
Impact of adherence to statins on chronic heart failure in primary prevention.British journal of clinical pharmacology, 66 5
(YiannakopoulouECPapadopulosJSCokkinosDV Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12:243–915942423)
YiannakopoulouECPapadopulosJSCokkinosDV Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12:243–915942423YiannakopoulouECPapadopulosJSCokkinosDV Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12:243–915942423, YiannakopoulouECPapadopulosJSCokkinosDV Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12:243–915942423
(BurnierM Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000;5 Suppl 1:S31–410904240)
BurnierM Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000;5 Suppl 1:S31–410904240BurnierM Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000;5 Suppl 1:S31–410904240, BurnierM Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000;5 Suppl 1:S31–410904240
S. Cutrona, N. Choudhry, M. Stedman, Amber Servi, J. Liberman, T. Brennan, M. Fischer, M. Brookhart, W. Shrank, W. Shrank (2010)
Physician Effectiveness in Interventions to Improve Cardiovascular Medication Adherence: A Systematic ReviewJournal of General Internal Medicine, 25
(PerreaultSDragomirABlaisL Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008;66:706–1618754842)
PerreaultSDragomirABlaisL Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008;66:706–1618754842PerreaultSDragomirABlaisL Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008;66:706–1618754842, PerreaultSDragomirABlaisL Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008;66:706–1618754842
R. Hansen, S. Dusetzina, Rosalie Dominik, B. Gaynes (2010)
Prescription refill records as a screening tool to identify antidepressant non‐adherencePharmacoepidemiology and Drug Safety, 19
(VinkNMKlungelOHStolkRP Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf 2009;18:159–6519109809)
VinkNMKlungelOHStolkRP Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf 2009;18:159–6519109809VinkNMKlungelOHStolkRP Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf 2009;18:159–6519109809, VinkNMKlungelOHStolkRP Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf 2009;18:159–6519109809
(BalkrishnanR The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 2005;43:517–2015908845)
BalkrishnanR The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 2005;43:517–2015908845BalkrishnanR The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 2005;43:517–2015908845, BalkrishnanR The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 2005;43:517–2015908845
(PietteJDHeislerMKreinS The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med 2005;165:1749–5516087823)
PietteJDHeislerMKreinS The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med 2005;165:1749–5516087823PietteJDHeislerMKreinS The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med 2005;165:1749–5516087823, PietteJDHeislerMKreinS The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med 2005;165:1749–5516087823
R. Chapman, E. Pelletier, Paula Smith, C. Roberts (2009)
Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?Patient preference and adherence, 3
(AvornJ Medication use in older patients: better policy could encourage better practice. JAMA 2010;304:1606–720940388)
AvornJ Medication use in older patients: better policy could encourage better practice. JAMA 2010;304:1606–720940388AvornJ Medication use in older patients: better policy could encourage better practice. JAMA 2010;304:1606–720940388, AvornJ Medication use in older patients: better policy could encourage better practice. JAMA 2010;304:1606–720940388
M. Krousel‐Wood, Sheila Thomas, P. Muntner, D. Morisky (2004)
Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patientsCurrent Opinion in Cardiology, 19
S. Karve, M. Cleves, M. Helm, T. Hudson, D. West, B. Martin (2008)
An Empirical Basis for Standardizing Adherence Measures Derived From Administrative Claims Data Among Diabetic PatientsMedical Care, 46
C. Dormuth, A. Patrick, W. Shrank, J. Wright, R. Glynn, J. Sutherland, M. Brookhart (2009)
Statin Adherence and Risk of Accidents: A Cautionary TaleCirculation, 119
Loren Miller, Loren Miller, Honghu Liu, R. Hays, C. Golin, C. Beck, S. Asch, Yingying Ma, A. Kaplan, N. Wenger (2007)
How well do clinicians estimate patients’ adherence to combination antiretroviral therapy?Journal of General Internal Medicine, 17
Arch Intern Med, 166
P. Rodgers, D. Ruffin (1998)
Medication nonadherence--Part I: The health and humanistic consequences.Managed care interface, 11 8
(SteinerJF Can we identify clinical predictors of medication adherence. and should we? Med Care 2010;48:193–520182266)
SteinerJF Can we identify clinical predictors of medication adherence. and should we? Med Care 2010;48:193–520182266SteinerJF Can we identify clinical predictors of medication adherence. and should we? Med Care 2010;48:193–520182266, SteinerJF Can we identify clinical predictors of medication adherence. and should we? Med Care 2010;48:193–520182266
R. Balkrishnan (2005)
The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know.Medical care, 43 6
(ChapmanRHPelletierEMSmithPJ Can adherence to antihypertensive therapy be used to promote adherence to statin therapy? Patient Prefer Adherence 2009;3:265–7519936170)
ChapmanRHPelletierEMSmithPJ Can adherence to antihypertensive therapy be used to promote adherence to statin therapy? Patient Prefer Adherence 2009;3:265–7519936170ChapmanRHPelletierEMSmithPJ Can adherence to antihypertensive therapy be used to promote adherence to statin therapy? Patient Prefer Adherence 2009;3:265–7519936170, ChapmanRHPelletierEMSmithPJ Can adherence to antihypertensive therapy be used to promote adherence to statin therapy? Patient Prefer Adherence 2009;3:265–7519936170
(HaynesRBMcDonaldHPGargAX Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880–312472330)
HaynesRBMcDonaldHPGargAX Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880–312472330HaynesRBMcDonaldHPGargAX Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880–312472330, HaynesRBMcDonaldHPGargAX Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880–312472330
N. Vink, Olaf Klungel, Ronald Stolk, Petra Denig (2009)
Comparison of various measures for assessing medication refill adherence using prescription dataPharmacoepidemiology and Drug Safety, 18
(MillerLGLiuHHaysRD How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002;17:1–1111903770)
MillerLGLiuHHaysRD How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002;17:1–1111903770MillerLGLiuHHaysRD How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002;17:1–1111903770, MillerLGLiuHHaysRD How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002;17:1–1111903770
S. Karve, M. Cleves, M. Helm, T. Hudson, D. West, B. Martin (2009)
Good and poor adherence: optimal cut-point for adherence measures using administrative claims dataCurrent Medical Research and Opinion, 25
(CramerJA Optimizing long-term patient compliance. Neurology 1995;45(2 Suppl 1):S25–87885587)
CramerJA Optimizing long-term patient compliance. Neurology 1995;45(2 Suppl 1):S25–87885587CramerJA Optimizing long-term patient compliance. Neurology 1995;45(2 Suppl 1):S25–87885587, CramerJA Optimizing long-term patient compliance. Neurology 1995;45(2 Suppl 1):S25–87885587
(CrystalSAkincigilABilderS Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care 2007;45(10 Suppl 2):S58–6517909385)
CrystalSAkincigilABilderS Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care 2007;45(10 Suppl 2):S58–6517909385CrystalSAkincigilABilderS Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care 2007;45(10 Suppl 2):S58–6517909385, CrystalSAkincigilABilderS Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care 2007;45(10 Suppl 2):S58–6517909385
R. Murri, A. Ammassari, M. Trotta, A. Luca, S. Melzi, C. Minardi, M. Zaccarelli, Patrizia Rellecati, P. Santopadre, F. Soscia, A. Scasso, V. Tozzi, M. Ciardi, G. Orofino, P. Noto, A. Monforte, A. Antinori, A. Wu, the Group (2004)
Patient-reported and physician-estimated adherence to HAARTJournal of General Internal Medicine, 19
(SenstBLAchusimLEGenestRP Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001;58:1126–3211449856)
SenstBLAchusimLEGenestRP Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001;58:1126–3211449856SenstBLAchusimLEGenestRP Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001;58:1126–3211449856, SenstBLAchusimLEGenestRP Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001;58:1126–3211449856
(DormuthCRPatrickARShrankWH Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051–719349320)
DormuthCRPatrickARShrankWH Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051–719349320DormuthCRPatrickARShrankWH Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051–719349320, DormuthCRPatrickARShrankWH Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051–719349320
(PattonKMeyersJLewisBE Enhancement of compliance among patients with hypertension. Am J Manag Care 1997;3:1693–810178467)
PattonKMeyersJLewisBE Enhancement of compliance among patients with hypertension. Am J Manag Care 1997;3:1693–810178467PattonKMeyersJLewisBE Enhancement of compliance among patients with hypertension. Am J Manag Care 1997;3:1693–810178467, PattonKMeyersJLewisBE Enhancement of compliance among patients with hypertension. Am J Manag Care 1997;3:1693–810178467
(TamblynRReidelKHuangA Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med Decis Making 2010;30:176–8819675319)
TamblynRReidelKHuangA Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med Decis Making 2010;30:176–8819675319TamblynRReidelKHuangA Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med Decis Making 2010;30:176–8819675319, TamblynRReidelKHuangA Increasing the detection and response to adherence problems with cardiovascular medication in primary care through computerized drug management systems: a randomized controlled trial. Med Decis Making 2010;30:176–8819675319
S. Crystal, A. Akincigil, S. Bilder, J. Walkup (2007)
Studying Prescription Drug Use and Outcomes With Medicaid Claims Data: Strengths, Limitations, and StrategiesMedical Care, 45
B. Patel, R. Leslie, P. Thiebaud, M. Nichol, Simon Tang, H. Solomon, D. Honda, J. Foody (2008)
Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimenVascular Health and Risk Management, 4
(ModiACRauschJRGlauserTA Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. JAMA 2011;305:1669–7621521848)
ModiACRauschJRGlauserTA Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. JAMA 2011;305:1669–7621521848ModiACRauschJRGlauserTA Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. JAMA 2011;305:1669–7621521848, ModiACRauschJRGlauserTA Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. JAMA 2011;305:1669–7621521848
J. Avorn (2010)
Medication use in older patients: better policy could encourage better practice.JAMA, 304 14
K. Patton, J. Meyers, B. Lewis (1997)
Enhancement of compliance among patients with hypertension.The American journal of managed care, 3 11
(HoPMRumsfeldJSMasoudiFA Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836–4117000939)
HoPMRumsfeldJSMasoudiFA Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836–4117000939HoPMRumsfeldJSMasoudiFA Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836–4117000939, HoPMRumsfeldJSMasoudiFA Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836–4117000939
M. Brookhart, A. Patrick, S. Schneeweiss, J. Avorn, C. Dormuth, W. Shrank, B. Wijk, B. Wijk, S. Cadarette, C. Canning, D. Solomon (2007)
Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use.Archives of internal medicine, 167 8
A. Modi, J. Rausch, T. Glauser (2011)
Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy.JAMA, 305 16
(OsterbergLBlaschkeT Adherence to medication. N Engl J Med 2005;353:487–9716079372)
OsterbergLBlaschkeT Adherence to medication. N Engl J Med 2005;353:487–9716079372OsterbergLBlaschkeT Adherence to medication. N Engl J Med 2005;353:487–9716079372, OsterbergLBlaschkeT Adherence to medication. N Engl J Med 2005;353:487–9716079372
J. Steiner (2010)
Can we identify clinical predictors of medication adherence... and should we?Medical care, 48 3
(KarveSClevesMAHelmM Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009;12:989–9519402852)
KarveSClevesMAHelmM Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009;12:989–9519402852KarveSClevesMAHelmM Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009;12:989–9519402852, KarveSClevesMAHelmM Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health 2009;12:989–9519402852
R. Haynes, H. Mcdonald, A. Garg (2002)
Helping patients follow prescribed treatment: clinical applications.JAMA, 288 22
David Chan, W. Shrank, D. Cutler, Saira Jan, M. Fischer, Jun Liu, J. Avorn, D. Solomon, A. Brookhart, N. Choudhry (2010)
Patient, Physician, and Payment Predictors of Statin AdherenceMedical Care, 48
E. Yiannakopoulou, J. Papadopulos, D. Cokkinos, T. Mountokalakis (2005)
Adherence to antihypertensive treatment: a critical factor for blood pressure controlEuropean Journal of Preventive Cardiology, 12
M. Murray, J. Harrison (2010)
Prescription Abandonment: Another Path to Medication NonadherenceAnnals of Internal Medicine, 153
N Engl J Med, 353
(ChoudhryNKFischerMAAvornJ The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011;171:814–2221555659)
ChoudhryNKFischerMAAvornJ The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011;171:814–2221555659ChoudhryNKFischerMAAvornJ The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011;171:814–2221555659, ChoudhryNKFischerMAAvornJ The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011;171:814–2221555659
P. McDonnell, M. Jacobs (2002)
Hospital Admissions Resulting from Preventable Adverse Drug ReactionsAnnals of Pharmacotherapy, 36
(HansenRADusetzinaSBDominikRC Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol Drug Saf 2010;19:33–719998397)
HansenRADusetzinaSBDominikRC Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol Drug Saf 2010;19:33–719998397HansenRADusetzinaSBDominikRC Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol Drug Saf 2010;19:33–719998397, HansenRADusetzinaSBDominikRC Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol Drug Saf 2010;19:33–719998397
A. Zygmunt, M. Olfson, C. Boyer, D. Mechanic (2002)
Interventions to improve medication adherence in schizophrenia.The American journal of psychiatry, 159 10
(RodgersPTRuffinDM Medication nonadherence—Part I: the health and humanistic consequences. Manag Care Interface 1998;11:58–6010182240)
RodgersPTRuffinDM Medication nonadherence—Part I: the health and humanistic consequences. Manag Care Interface 1998;11:58–6010182240RodgersPTRuffinDM Medication nonadherence—Part I: the health and humanistic consequences. Manag Care Interface 1998;11:58–6010182240, RodgersPTRuffinDM Medication nonadherence—Part I: the health and humanistic consequences. Manag Care Interface 1998;11:58–6010182240
(2010)
Establishing a Drug Era Persistence Window for Active Surveillance
J. Augustine, A. Dietrich (1998)
Emergency medicine in a managed care environment.Managed care interface, 11 2
Eur J Cardiovasc Prev Rehabil, 12
(Krousel-WoodMThomasSMuntnerP Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357–6215218396)
Krousel-WoodMThomasSMuntnerP Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357–6215218396Krousel-WoodMThomasSMuntnerP Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357–6215218396, Krousel-WoodMThomasSMuntnerP Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357–6215218396
Michel Burnier (2000)
Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension.Blood pressure monitoring, 5 Suppl 1
(SiegelDLopezJMeierJ Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med 2007;120:26–3217208076)
SiegelDLopezJMeierJ Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med 2007;120:26–3217208076SiegelDLopezJMeierJ Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med 2007;120:26–3217208076, SiegelDLopezJMeierJ Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med 2007;120:26–3217208076
(RyanP Establishing a Drug Era Persistence Window for Active Surveillance. Foundation for the National Institutes of Health, 2010 http://omop.fnih.org/sites/default/files/OMOP-Establishing%20a%20Drug%20Era%20Persistence%20Window%20for%20Active%20Surveillance-Jan%202010.pdf)
RyanP Establishing a Drug Era Persistence Window for Active Surveillance. Foundation for the National Institutes of Health, 2010 http://omop.fnih.org/sites/default/files/OMOP-Establishing%20a%20Drug%20Era%20Persistence%20Window%20for%20Active%20Surveillance-Jan%202010.pdfRyanP Establishing a Drug Era Persistence Window for Active Surveillance. Foundation for the National Institutes of Health, 2010 http://omop.fnih.org/sites/default/files/OMOP-Establishing%20a%20Drug%20Era%20Persistence%20Window%20for%20Active%20Surveillance-Jan%202010.pdf, RyanP Establishing a Drug Era Persistence Window for Active Surveillance. Foundation for the National Institutes of Health, 2010 http://omop.fnih.org/sites/default/files/OMOP-Establishing%20a%20Drug%20Era%20Persistence%20Window%20for%20Active%20Surveillance-Jan%202010.pdf
B. Senst, L. Achusim, R. Genest, L. Cosentino, C. Ford, J. Little, S. Raybon, D. Bates (2001)
Practical approach to determining costs and frequency of adverse drug events in a health care network.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 58 12
(ZygmuntAOlfsonMBoyerCA Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653–6412359668)
ZygmuntAOlfsonMBoyerCA Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653–6412359668ZygmuntAOlfsonMBoyerCA Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653–6412359668, ZygmuntAOlfsonMBoyerCA Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159:1653–6412359668
(MurrayMDHarrisonJ Prescription abandonment: another path to medication nonadherence. Ann Intern Med 2010;153:680–121079227)
MurrayMDHarrisonJ Prescription abandonment: another path to medication nonadherence. Ann Intern Med 2010;153:680–121079227MurrayMDHarrisonJ Prescription abandonment: another path to medication nonadherence. Ann Intern Med 2010;153:680–121079227, MurrayMDHarrisonJ Prescription abandonment: another path to medication nonadherence. Ann Intern Med 2010;153:680–121079227
S. Karve, M. Cleves, M. Helm, T. Hudson, D. West, B. Martin (2009)
Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 12 6
J. Cramer (1995)
Optimizing long-term patient compliance.Neurology, 45 2 Suppl 1
(CutronaSLChoudhryNKStedmanM Physician effectiveness in interventions to improve cardiovascular medication adherence: a systematic review. J Gen Intern Med 2010;25:1090–620464522)
CutronaSLChoudhryNKStedmanM Physician effectiveness in interventions to improve cardiovascular medication adherence: a systematic review. J Gen Intern Med 2010;25:1090–620464522CutronaSLChoudhryNKStedmanM Physician effectiveness in interventions to improve cardiovascular medication adherence: a systematic review. J Gen Intern Med 2010;25:1090–620464522, CutronaSLChoudhryNKStedmanM Physician effectiveness in interventions to improve cardiovascular medication adherence: a systematic review. J Gen Intern Med 2010;25:1090–620464522
B. Vrijens, G. Vincze, P. Kristanto, J. Urquhart, M. Burnier (2008)
Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing historiesBMJ : British Medical Journal, 336
R. Tamblyn, K. Reidel, A. Huang, Laurel Taylor, N. Winslade, G. Bartlett, R. Grad, A. Jacques, M. Dawes, P. Larochelle, A. Pinsonneault (2010)
Increasing the Detection and Response to Adherence Problems with Cardiovascular Medication in Primary Care through Computerized Drug Management Systems: A Randomized Controlled TrialMedical Decision Making, 30
(McDonnellPJJacobsMR Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331–612196047)
McDonnellPJJacobsMR Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331–612196047McDonnellPJJacobsMR Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331–612196047, McDonnellPJJacobsMR Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331–612196047
(WuPHYangCYYaoZL Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens 2010;23:155–6019927135)
WuPHYangCYYaoZL Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens 2010;23:155–6019927135WuPHYangCYYaoZL Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens 2010;23:155–6019927135, WuPHYangCYYaoZL Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens 2010;23:155–6019927135
N. Choudhry, M. Fischer, J. Avorn, J. Liberman, S. Schneeweiss, J. Pakes, T. Brennan, W. Shrank (2011)
The implications of therapeutic complexity on adherence to cardiovascular medications.Archives of internal medicine, 171 9
(PatelBVLeslieRSThiebaudP Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4:673–8118827917)
PatelBVLeslieRSThiebaudP Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4:673–8118827917PatelBVLeslieRSThiebaudP Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4:673–8118827917, PatelBVLeslieRSThiebaudP Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4:673–8118827917
D. Siegel, Julio Lopez, J. Meier (2007)
Antihypertensive medication adherence in the Department of Veterans Affairs.The American journal of medicine, 120 1
(ChanDCShrankWHCutlerD Patient, physician, and payment predictors of statin adherence. Med Care 2010;48:196–20219890219)
ChanDCShrankWHCutlerD Patient, physician, and payment predictors of statin adherence. Med Care 2010;48:196–20219890219ChanDCShrankWHCutlerD Patient, physician, and payment predictors of statin adherence. Med Care 2010;48:196–20219890219, ChanDCShrankWHCutlerD Patient, physician, and payment predictors of statin adherence. Med Care 2010;48:196–20219890219
Pin-Hsuan Wu, Chuh-Yuh Yang, Zhi Yao, Wei-Zhan Lin, Li-Wei Wu, Chih‐Ching Chang (2010)
Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan.American journal of hypertension, 23 2
J. Piette, M. Heisler, S. Krein, E. Kerr (2005)
The role of patient-physician trust in moderating medication nonadherence due to cost pressures.Archives of internal medicine, 165 15
(RossFM Patient compliance—whose responsibility? Soc Sci Med 1991;32:89–942008627)
RossFM Patient compliance—whose responsibility? Soc Sci Med 1991;32:89–942008627RossFM Patient compliance—whose responsibility? Soc Sci Med 1991;32:89–942008627, RossFM Patient compliance—whose responsibility? Soc Sci Med 1991;32:89–942008627
(BrookhartMAPatrickARSchneeweissS Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007;167:847–5217452550)
BrookhartMAPatrickARSchneeweissS Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007;167:847–5217452550BrookhartMAPatrickARSchneeweissS Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007;167:847–5217452550, BrookhartMAPatrickARSchneeweissS Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007;167:847–5217452550
L. Kennedy (2007)
Effect of Medication Nonadherence on Hospitalization and Mortality Among Patients With Diabetes MellitusYearbook of Endocrinology, 2007
(VrijensBVinczeGKristantoP Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114–1718480115)
VrijensBVinczeGKristantoP Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114–1718480115VrijensBVinczeGKristantoP Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114–1718480115, VrijensBVinczeGKristantoP Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114–1718480115
(SimpsonSHEurichDTMajumdarSR A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:1516790458)
SimpsonSHEurichDTMajumdarSR A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:1516790458SimpsonSHEurichDTMajumdarSR A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:1516790458, SimpsonSHEurichDTMajumdarSR A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:1516790458
S. Simpson, D. Eurich, S. Majumdar, R. Padwal, R. Tsuyuki, J. Varney, Jeffrey Johnson (2006)
A meta-analysis of the association between adherence to drug therapy and mortalityBMJ : British Medical Journal, 333
AbstractBackground We sought to measure population-level adherence to antihyperlipidemics, antihypertensives, and oral hypoglycemics, and to develop a model for early identification of subjects at high risk of long-term poor adherence.Methods Prescription-filling data for 2 million subjects derived from a payor's insurance claims were used to evaluate adherence to three chronic drugs over 1 year. We relied on patterns of prescription fills, including the length of gaps in medication possession, to measure adherence among subjects and to build models for predicting poor long-term adherence.Results All prescription fills for a specific drug were sequenced chronologically into drug eras. 61.3% to 66.5% of the prescription patterns contained medication gaps >30 days during the first year of drug use. These interrupted drug eras include long-term discontinuations, where the subject never again filled a prescription for any drug in that category in the dataset, which represent 23.7% to 29.1% of all drug eras. Among the prescription-filling patterns without large medication gaps, 0.8% to 1.3% exhibited long-term poor adherence. Our models identified these subjects as early as 60 days after the first prescription fill, with an area under the curve (AUC) of 0.81. Model performance improved as the predictions were made at later time-points, with AUC values increasing to 0.93 at the 120-day time-point.Conclusions Dispensed medication histories (widely available in real time) are useful for alerting providers about poorly adherent patients and those who will be non-adherent several months later. Efforts to use these data in point of care and decision support facilitating patient are warranted.
Journal of the American Medical Informatics Association – Oxford University Press
Published: Jul 19, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.